Navigation Links
Clinic puts patients at heart of multiple sclerosis research
Date:8/31/2010

A research clinic for multiple sclerosis patients is being set up with a 10 million donation from the author J K Rowling.

The Anne Rowling Regenerative Neurology Clinic at the University of Edinburgh will place patients at the heart of research to improve outcomes for multiple sclerosis sufferers.

This will focus on patient-based studies to help find treatments that could slow progression of the disease, working towards the eventual aim of stopping and reversing it.

The Anne Rowling Regenerative Neurology Clinic is named after Ms Rowling's mother, who died of multiple sclerosis aged 45.

Work at the clinic will also provide insight into other degenerative neurological conditions, such as Alzheimer's disease, Parkinson's disease, Huntington's disease and Motor Neurone Disease.

As with multiple sclerosis, these disorders are progressive and incurable.

The clinic follows on from the setting up of the Centre for Multiple Sclerosis Research at the University in 2007, which has also received support from the Harry Potter author.

Ms Rowling said: "I cannot think of anything more important, or of more lasting value, than to help the university attract world-class minds in the field of neuroregeneration, to build on its long and illustrious history of medical research and, ultimately, to seek a cure for a very Scottish disease." (A full statement from J K Rowling is below.)

The Anne Rowling Regenerative Neurology Clinic will be based in a purpose-built facility within the University's Chancellor's Building, next to the city's Royal Infirmary and within Edinburgh BioQuarter at Little France. This development will build on Edinburgh's strong track records in patient-focused clinical research on neurological disorders and in imaging of the brain and nervous system.

It is the single largest donation that the author has given to a charitable cause. This is also the largest single donation that the University has received.

Clinical academics will work closely with a critical mass of researchers studying neurodegenerative disorders already based at the University.

This will include expertise from the Centre for Multiple Sclerosis Research, the MRC Centre for Regenerative Medicine, the Centre for Neuroregeneration, Euan MacDonald Centre for Motor Neuron Disease Research and Division of Clinical Sciences.

There will also be a major emphasis on training the next generation of researchers.

Professor Sir Timothy O'Shea, Principal of the University of Edinburgh, said: "This exceptionally generous donation will provide great help in the worldwide effort to improve treatments for multiple sclerosis. Work at the clinic will build on the already existing important research strengths in neurodegenerative disorders at the University, which benefit very considerably from our close partnership with NHS Lothian."

Multiple sclerosis affects around 100,000 people in the UK. Scotland has one of the highest rates of multiple sclerosis in the world, with some 10,500 people with the condition.

While there is some evidence to suggest that multiple sclerosis is caused by a combination of genetics and environmental factors the exact cause of the disease is not fully understood.

Professor Charles ffrench-Constant, co- director of the University of Edinburgh's Centre for Multiple Sclerosis Research and Director-elect the MRC Centre of Regenerative Medicine, said: "We can only find improved treatments if we can truly understand diseases and the biological processes behind them. The Anne Rowling Regenerative Neurology Clinic will enable us to carry out studies that can inform laboratory research and, in turn, this knowledge can be translated back into treatments for patients."

Multiple sclerosis causes myelin a protective layer surrounding nerve cells in the brain to break down. This then leads to the nerve cells, which send messages from the brain to other parts of the body, becoming damaged.

This can cause symptoms such as numbness, visual loss, fatigue, dizziness and weakness that lead to accumulating disability.

As with other neurological disorders, once the nerve cells are damaged they are not replaced causing the condition to progressively worsen.

Siddharthan Chandran, Professor of Neurology and co-director of the Centre for Multiple Sclerosis Research, said: "Multiple sclerosis has many features in common with other neurodegenerative disorders. As a result any discoveries from the Anne Rowling Regenerative Neurology Clinic will help us advance our understanding and treatment of all these related neurological diseases. Finding ways to slow progression of these conditions will make an enormous difference to patients' lives."

The donation is part of the Edinburgh Campaign, which aims to raise 350 million for initiatives across the University. This includes creating new hubs of learning, conserving iconic University buildings, furthering research and increasing the number of scholarships and bursaries available for students.


'/>"/>

Contact: Tara Womersley
tara.womersley@ed.ac.uk
01-316-509-836
University of Edinburgh
Source:Eurekalert

Related medicine news :

1. The West Clinic Joins Cancer Clinics of Excellence (CCE)
2. Stethoscope App gives iPhone New Clinical Skills
3. Mayo Clinic responsible for $22 billion in economic impact, including $9.6 billion in Minnesota
4. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
5. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
6. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
7. Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories
8. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
9. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
10. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
11. International Merchant Advisors CEO Mel Roseman to Discuss New Medical Marijuana Clinics Live on CBS Radio Networks Big Biz Show February 22, 2010 at 1:40 pm PST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports ... a study released today at the 1st Pan American Parkinson’s and Movement Disorders ... be effective in improving cognitive function in PD patients. This study, led by ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, ... Go. Core benefits and advantages built into the home office sit stand solution ... and feel. Ability to gain the benefits embedded in the TaskMate Go are ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , The ... recognition opportunities as well as advocacy for the state and region‘s technology businesses, ... 23. The Council's Innovation Forecast event highlights innovation throughout the region from ...
(Date:2/24/2017)... ... ... The Smart Machine Age is here, and it’s disrupting everything. Not only could ... in the United States may be taken over by technology in the next five ... steamrolls over colleagues is drawing to a close. Success will belong to those who ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Healthcare ... The Medical Center at Craig Ranch building at 8080 State Highway 121, Suite 210, ... District with easy access to Highway 121. , As the practice has grown, the ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 2017   Royal Philips (NYSE: ... in health technology, today announced 510(k) clearance from ... market its ElastQ Imaging capability, further expanding the ... ElastQ Imaging enables simultaneous imaging of tissue and ... the diagnosis of various liver conditions. With ElastQ ...
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
(Date:2/27/2017)... , Feb. 27, 2017  CTI BioPharma Corp. (CTI BioPharma) ... Adam Craig , M.D., Ph.D., as President and Chief Executive ... March 20, 2017. Dr. Craig succeeds Richard Love , ... the company,s Board of Directors.  Dr. Craig has over 20 ... both the US and Europe . ...
Breaking Medicine Technology: